146 related articles for article (PubMed ID: 15132325)
1. Current recommendations for extended out-of-hospital thromboprophylaxis following total hip arthroplasty.
Krotenberg R
Am J Orthop (Belle Mead NJ); 2004 Apr; 33(4):180-4. PubMed ID: 15132325
[TBL] [Abstract][Full Text] [Related]
2. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
3. DVT prophylaxis: better living through chemistry: affirms.
Pellegrini VD
Orthopedics; 2010 Sep; 33(9):642. PubMed ID: 20839678
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolic prophylaxis following total hip arthroplasty: a North American perspective.
Clark CR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):12-9. PubMed ID: 12349890
[TBL] [Abstract][Full Text] [Related]
5. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of thromboprophylaxis in the management of total hip and knee arthroplasty.
Skinner HB; Schulz MM
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):20-30. PubMed ID: 12349892
[TBL] [Abstract][Full Text] [Related]
7. Rationale for thromboprophylaxis in lower joint arthroplasty.
Colwell CW
Am J Orthop (Belle Mead NJ); 2007 Sep; 36(9 Suppl):11-3. PubMed ID: 17948162
[TBL] [Abstract][Full Text] [Related]
8. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
9. The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty.
Colwell CW
Orthopedics; 2009 Dec; 32(12 Suppl):67-73. PubMed ID: 20201479
[TBL] [Abstract][Full Text] [Related]
10. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
11. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership.
Mesko JW; Brand RA; Iorio R; Gradisar I; Heekin R; Leighton R; Thornberry R
J Arthroplasty; 2001 Sep; 16(6):679-88. PubMed ID: 11547365
[TBL] [Abstract][Full Text] [Related]
13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
14. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
15. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
[TBL] [Abstract][Full Text] [Related]
16. The role of low molecular weight heparin in total knee arthroplasty.
Iobst CA; Friedman RJ
Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism following total knee replacement.
Choi BY; Huo MH
J Surg Orthop Adv; 2007; 16(1):31-5. PubMed ID: 17371645
[TBL] [Abstract][Full Text] [Related]
18. Deep vein thrombosis prophylaxis: a comprehensive approach for total hip and total knee arthroplasty patient populations.
Miric A; Lombardi P; Sculco TP
Am J Orthop (Belle Mead NJ); 2000 Apr; 29(4):269-74. PubMed ID: 10784014
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolic disease after total hip and knee arthroplasty: current perspectives in a regulated environment.
Pellegrini VD; Sharrock NE; Paiement GD; Morris R; Warwick DJ
Instr Course Lect; 2008; 57():637-61. PubMed ID: 18399613
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.
Hull RD; Pineo GF; Francis C; Bergqvist D; Fellenius C; Soderberg K; Holmqvist A; Mant M; Dear R; Baylis B; Mah A; Brant R
Arch Intern Med; 2000 Jul; 160(14):2208-15. PubMed ID: 10904465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
